Anixa Biosciences Announces Treatment Of Third Patient In Ovarian Cancer CAR-T Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences has announced the treatment of the third patient in its ovarian cancer CAR-T clinical trial. This marks a significant step in the company's ongoing research and development efforts in the field of cancer treatment.
August 28, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences' announcement of the treatment of the third patient in its ovarian cancer CAR-T clinical trial could potentially boost investor confidence in the company's R&D capabilities.
The announcement indicates progress in Anixa Biosciences' research and development efforts. This could potentially attract more investors, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100